Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 3/20 | 0.37 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | RET | P07949 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.33 |
| ▸ | RXRA | P19793 | 1/20 | 0.32 |
| ▸ | RXRB | P28702 | 1/20 | 0.32 |
| ▸ | RXRG | P48443 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30724102 | 1.00 | CYP4F2 (0.37) | CYP4F2CYP4A11PDE10ARETALDH1A1 | |
| SCHEMBL30861031 | 0.85 | GAA (0.44) | CYP4F2CYP4A11PDE10ARETALDH1A1 | |
| SCHEMBL27227964 | 0.85 | GAA (0.44) | CYP4F2CYP4A11PDE10ARETALDH1A1 | |
| SCHEMBL15265438 | 0.85 | CYP4F2 (0.37) | CYP4F2CYP4A11PDE10ARETALDH1A1 | |
| SCHEMBL15266811 | 0.80 | CYP4F2 (0.34) | CYP4F2CYP4A11RETALDH1A1POLB | |
| SCHEMBL25281611 | 0.79 | CYP4F2 (0.33) | CYP4F2CYP4A11RETALDH1A1POLB | |
| SCHEMBL19485522 | 0.79 | MAP3K5 (0.39) | CYP4F2CYP4A11PDE10ARETALDH1A1 | |
| SCHEMBL29879089 | 0.79 | MAP3K5 (0.39) | CYP4F2CYP4A11PDE10ARETALDH1A1 | |
| SCHEMBL24268660 | 0.79 | MAP3K5 (0.39) | CYP4F2CYP4A11PDE10ARETALDH1A1 | |
| SCHEMBL15278583 | 0.78 | CREBBP (0.35) | CYP4F2CYP4A11MAP3K5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242507-A1 | INDAZOLE-FUSED CYCLIC COMPOUND | Zhejiang Yangli Pharmaceutical Technology Co., Ltd. (CN) | 2023-08-03 | — | — | US | disclosed |
| US-20230242507-A1 | INDAZOLE-FUSED CYCLIC COMPOUND | Zhejiang Yangli Pharmaceutical Technology Co., Ltd. (CN) | 2023-08-03 | — | — | US | disclosed |
| WO-2023125700-A1 | SALT FORM AND CRYSTAL FORM OF TETRAHYDROCYCLOHEPTA INDAZOLE COMPOUND | 南京明德新药研发有限公司 | 2023-07-06 | — | — | WO | disclosed |
| EP-4174059-A1 | INDAZOLE-FUSED CYCLIC COMPOUND | Medshine Discovery Inc. (CN) | 2023-05-03 | — | — | EP | disclosed |
| WO-2022001971-A1 | INDAZOLE-FUSED CYCLIC COMPOUND | 南京明德新药研发有限公司 | 2022-01-06 | — | — | WO | disclosed |
| EP-2828243-B1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | SERAGON PHARMACEUTICALS INC (US) | 2018-10-17 | — | — | EP | disclosed |
| US-9499538-B2 | Estrogen receptor modulators and uses thereof | SERAGON PHARMACEUTICALS, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-9499538-B2 | Estrogen receptor modulators and uses thereof | SERAGON PHARMACEUTICALS, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-20150105403-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | SERAGON PHARMACEUTICALS, INC. | 2015-04-16 | — | — | US | disclosed |
| US-20150105403-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | SERAGON PHARMACEUTICALS, INC. | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105403-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, ESRRG, GPER1 | CYP4F2 604/4885CYP4A11 131/4885PDE10A 2650/4885 |
| US-20230242507-A1 | INDAZOLE-FUSED CYCLIC COMPOUND | SLC5A11, CYP11B2, CYP4F11 | CYP4F2 33/4885CYP4A11 4/4885PDE10A 500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.